Quantitative MRI in Multiple Sclerosis: From Theory to Application

References

1. 1.↵
   1. Rovira À,
   2. Wattjes MP,
   3. Tintoré M, et al

   ; MAGNIMS Study Group. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol 2015;11:471–82 doi:10.1038/nrneurol.2015.106 pmid:26149978

   CrossRefPubMed
2. 2.↵
   1. Wattjes MP,
   2. Ciccarelli O,
   3. Reich DS, et al

   ; North American Imaging in Multiple Sclerosis Cooperative MRI Guidelines Working Group. MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 2021;20:653–70 doi:10.1016/S1474-4422(21)00095-8 pmid:34139157

   CrossRefPubMed
3. 3.↵
   1. Hagiwara A,
   2. Otsuka Y,
   3. Andica C, et al

   . Differentiation between multiple sclerosis and neuromyelitis optica spectrum disorders by multiparametric quantitative MRI using convolutional neural network. J Clin Neurosci 2021;87:55–58 doi:10.1016/j.jocn.2021.02.018 pmid:33863534

   CrossRefPubMed
4. 4.↵
   1. Pudlac A,
   2. Burgetova A,
   3. Dusek P, et al

   . Deep gray matter iron content in neuromyelitis optica and multiple sclerosis. BioMed Res Int 2020;2020:6492786 doi:10.1155/2020/6492786 pmid:32509866

   CrossRefPubMed
5. 5.↵
   1. Deistung A,
   2. Schweser F,
   3. Reichenbach JR

   . Overview of quantitative susceptibility mapping. NMR Biomed 2017;30:e3569 doi:10.1002/nbm.3569 pmid:27434134

   CrossRefPubMed
6. 6.↵
   1. Seiler A,
   2. Nöth U,
   3. Hok P, et al

   . Multiparametric quantitative MRI in neurological diseases. Front Neurol 2021;12:640239 doi:10.3389/fneur.2021.640239 pmid:33763021

   CrossRefPubMed
7. 7.↵
   1. Li J,
   2. Lin H,
   3. Liu T, et al

   . Quantitative susceptibility mapping (QSM) minimizes interference from cellular pathology in R2* estimation of liver iron concentration. J Magn Reson Imaging 2018;48:1069–79 doi:10.1002/jmri.26019 pmid:29566449

   CrossRefPubMed
8. 8.↵
   1. Banerjee R,
   2. Pavlides M,
   3. Tunnicliffe EM, et al

   . Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol 2014;60:69–77 doi:10.1016/j.jhep.2013.09.002 pmid:24036007

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Straub S,
   2. Laun FB,
   3. Emmerich J, et al

   . Potential of quantitative susceptibility mapping for detection of prostatic calcifications. J Magn Reson Imaging 2017;45:889– 98 doi:10.1002/jmri.25385 pmid:27418017

   CrossRefPubMed
10. 10.↵
    1. Jerban S,
    2. Lu X,
    3. Jang H, et al

    . Significant correlations between human cortical bone mineral density and quantitative susceptibility mapping (QSM) obtained with 3D cones ultrashort echo time magnetic resonance imaging (UTE-MRI). Magn Reson Imaging 2019;62:104–10 doi:10.1016/j.mri.2019.06.016 pmid:31247253

    CrossRefPubMed
11. 11.↵
    1. Karur GR,
    2. Hanneman K

    . Cardiac MRI T1, T2, and T2* mapping in clinical practice. Advances in Clinica Radiology 2019;1:27–41 doi:10.1016/j.yacr.2019.03.001

    CrossRef
12. 12.↵
    1. Granziera C,
    2. Wuerfel J,
    3. Barkhof F, et al

    ; MAGNIMS Study Group. Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis. Brain 2021;144:1296–1311 doi:10.1093/brain/awab029 pmid:33970206

    CrossRefPubMed
13. 13.↵
    1. Pontillo G,
    2. Cocozza S,
    3. Lanzillo R, et al

    . Determinants of deep gray matter atrophy in multiple sclerosis: a multimodal MRI study. AJNR Am J Neuroradiol 2019;40:99–106 doi:10.3174/ajnr.A5915 pmid:30573464

    Abstract/FREE Full Text
14. 14.↵
    1. Mehta V,
    2. Pei W,
    3. Yang G, et al

    . Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions. PLoS One 2013;8:e57573 doi:10.1371/journal.pone.0057573 pmid:23516409

    CrossRefPubMed
15. 15.↵
    1. Möller HE,
    2. Bossoni L,
    3. Connor JR, et al

    . Iron, myelin, and the brain: neuroimaging meets neurobiology. Trends Neurosci 2019;42:384–401 doi:10.1016/j.tins.2019.03.009 pmid:31047721

    CrossRefPubMed
16. 16.↵
    1. Deoni SC,
    2. Rutt BK,
    3. Peters TM

    . Rapid combined T1 and T2 mapping using gradient recalled acquisition in the steady state. Magn Reson Med 2003;49:515–26 doi:10.1002/mrm.10407 pmid:12594755

    CrossRefPubMed
17. 17.↵
    1. Yarnykh VL

    . Actual flip-angle imaging in the pulsed steady state: a method for rapid three-dimensional mapping of the transmitted radiofrequency field. Magn Reson Med 2007;57:192–200 doi:10.1002/mrm.21120 pmid:17191242

    CrossRefPubMed
18. 18.↵
    1. Palma G,
    2. Tedeschi E,
    3. Borrelli P, et al

    . A novel multiparametric approach to 3D quantitative MRI of the brain. PLoS One 2015;10:e0134963 doi:10.1371/journal.pone.0134963 pmid:26284778

    CrossRefPubMed
19. 19.↵
    1. Baudrexel S,
    2. Nöth U,
    3. Schüre JR, et al

    . T₁ mapping with the variable flip angle technique: a simple correction for insufficient spoiling of transverse magnetization. Magn Reson Med 2018;79:3082–92 doi:10.1002/mrm.26979 pmid:29052267

    CrossRefPubMed
20. 20.↵
    1. Björk M,
    2. Ingle RR,
    3. Gudmundson E, et al

    . Parameter estimation approach to banding artifact reduction in balanced steady-state free precession. Magn Reson Med 2014;72:880–92 doi:10.1002/mrm.24986 pmid:24166591

    CrossRefPubMed
21. 21.↵
    1. Monti S,
    2. Borrelli P,
    3. Tedeschi E, et al

    . RESUME: turning an SWI acquisition into a fast qMRI protocol. PLoS One 2017;12:e0189933 doi:10.1371/journal.pone.0189933 pmid:29261786

    CrossRefPubMed
22. 22.↵
    1. Monti S,
    2. Pontillo G,
    3. Russo C, et al

    . RESUME^N: a flexible class of multi-parameter qMRI protocols. Phys Med 2021;88:23–36 doi:10.1016/j.ejmp.2021.04.005 pmid:34171573

    CrossRefPubMed
23. 23.↵
    1. Li W,
    2. Wang N,
    3. Yu F, et al

    . A method for estimating and removing streaking artifacts in quantitative susceptibility mapping. Neuroimage 2015;108:111–22 doi:10.1016/j.neuroimage.2014.12.043 pmid:25536496

    CrossRefPubMed
24. 24.↵
    1. Li W,
    2. Wu B,
    3. Liu C

    . Quantitative susceptibility mapping of human brain reflects spatial variation in tissue composition. Neuroimage 2011;55:1645–56 doi:10.1016/j.neuroimage.2010.11.088 pmid:21224002

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Aja-Fernández S,
    2. Pieciak T,
    3. Vegas-Sánchez-Ferrero G

    . Spatially variant noise estimation in MRI: a homomorphic approach. Med Image Anal 2015;20:184–97 doi:10.1016/j.media.2014.11.005 pmid:25499191

    CrossRefPubMed
26. 26.↵
    1. Borrelli P,
    2. Palma G,
    3. Tedeschi E, et al

    . Improving signal-to-noise ratio in susceptibility weighted imaging: a novel multicomponent non-local approach. PLoS One 2015;10:e0126835 doi:10.1371/journal.pone.0126835 pmid:26030293

    CrossRefPubMed
27. 27.↵
    1. Filippi M,
    2. Bar-Or A,
    3. Piehl F, et al

    . Multiple sclerosis. Nat Rev Dis Primers 2018;4:43 doi:10.1038/s41572-018-0041-4 pmid:30410033

    CrossRefPubMed
28. 28.↵
    1. Allen IV,
    2. McQuaid S,
    3. Mirakhur M, et al

    . Pathological abnormalities in the normal-appearing white matter in multiple sclerosis. Neurolo Sci 2001;22:141–44 doi:10.1007/s100720170012 pmid:11603615

    CrossRefPubMed
29. 29.↵
    1. Hametner S,
    2. Wimmer I,
    3. Haider L, et al

    . Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol 2013;74:848–61 doi:10.1002/ana.23974 pmid:23868451

    CrossRefPubMed
30. 30.↵
    1. Stephenson E,
    2. Nathoo N,
    3. Mahjoub Y, et al

    . Iron in multiple sclerosis: roles in neurodegeneration and repair. Nat Rev Neurol 2014;10:459–68 doi:10.1038/nrneurol.2014.118 pmid:25002107

    CrossRefPubMed
31. 31.↵
    1. Weiskopf N,
    2. Edwards LJ,
    3. Helms G, et al

    . Quantitative magnetic resonance imaging of brain anatomy and in vivo histology. Nat Rev Phys 2021;3:570–88 doi:10.1038/s42254-021-00326-1

    CrossRef
32. 32.↵
    1. Wisnieff C,
    2. Ramanan S,
    3. Olesik J, et al

    . Quantitative susceptibility mapping (QSM) of white matter multiple sclerosis lesions: Interpreting positive susceptibility and the presence of iron. Magn Reson Med 2015;74:564–70 doi:10.1002/mrm.25420 pmid:25137340

    CrossRefPubMed
33. 33.↵
    1. Tofts PS

    1. Tofts PS

    . PD: proton density of tissue water. In: Tofts PS. Quantitative MRI of the Brain: Measuring Changes Caused by Disease. Wiley Online Library; 2003:85–109
34. 34.↵
    1. Eis M,
    2. Els T,
    3. Hoehn-Berlage M

    . High resolution quantitative relaxation and diffusion MRI of three different experimental brain tumors in rat. Magn Reson Med 1995;34:835–44 doi:10.1002/mrm.1910340608 pmid:8598810

    CrossRefPubMed
35. 35.↵
    1. Schmierer K,
    2. Wheeler-Kingshott CA,
    3. Tozer DJ, et al

    . Quantitative magnetic resonance of postmortem multiple sclerosis brain before and after fixation. Magn Reson Med 2008;59:268–77 doi:10.1002/mrm.21487 pmid:18228601

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Stüber C,
    2. Morawski M,
    3. Schäfer A, et al

    . Myelin and iron concentration in the human brain: a quantitative study of MRI contrast. Neuroimage 2014;93 Pt 1:95–106 doi:10.1016/j.neuroimage.2014.02.026 pmid:24607447

    CrossRefPubMed
37. 37.↵
    1. Bagnato F,
    2. Hametner S,
    3. Yao B, et al

    . Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla. Brain 2011;134:3602–15 doi:10.1093/brain/awr278 pmid:22171355

    CrossRefPubMed
38. 38.↵
    1. Hametner S,
    2. Endmayr V,
    3. Deistung A, et al

    . The influence of brain iron and myelin on magnetic susceptibility and effective transverse relaxation: a biochemical and histological validation study. Neuroimage 2018;179:117–33 doi:10.1016/j.neuroimage.2018.06.007 pmid:29890327

    CrossRefPubMed
39. 39.↵
    1. van der Valk P,
    2. De Groot CJ

    . Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. Neuropathol Appl Neurobiol 2000;26:2–10 doi:10.1046/j.1365-2990.2000.00217.x pmid:10736062

    CrossRefPubMedWeb of Science
40. 40.↵
    1. Frischer JM,
    2. Weigand SD,
    3. Guo Y, et al

    . Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol 2015;78:710–21 doi:10.1002/ana.24497 pmid:26239536

    CrossRefPubMed
41. 41.↵
    1. Tallantyre EC,
    2. Brookes MJ,
    3. Dixon JE, et al

    . Demonstrating the perivascular distribution of MS lesions in vivo with 7-Tesla MRI. Neurology 2008;70:2076–78 doi:10.1212/01.wnl.0000313377.49555.2e pmid:18505982

    CrossRefPubMed
42. 42.↵
    1. Gaitán MI,
    2. Shea CD,
    3. Evangelou IE, et al

    . Evolution of the blood-brain barrier in newly forming multiple sclerosis lesions. Ann Neurol 2011;70:22–29 doi:10.1002/ana.22472 pmid:21710622

    CrossRefPubMed
43. 43.↵
    1. Blystad I,
    2. Håkansson I,
    3. Tisell A, et al

    . Quantitative MRI for analysis of active multiple sclerosis lesions without gadolinium-based contrast agent. AJNR Am J Neuroradiol 2016;37:94–100 doi:10.3174/ajnr.A4501 pmid:26471751

    Abstract/FREE Full Text
44. 44.↵
    1. Hagiwara A,
    2. Hori M,
    3. Yokoyama K, et al

    . Utility of a multiparametric quantitative MRI model that assesses myelin and edema for evaluating plaques, periplaque white matter, and normal-appearing white matter in patients with multiple sclerosis: a feasibility study. AJNR Am J Neuroradiol 2017;38:237–42 doi:10.3174/ajnr.A4977 pmid:27789453

    Abstract/FREE Full Text
45. 45.↵
    1. Zhang Y,
    2. Gauthier SA,
    3. Gupta A, et al

    . Quantitative susceptibility mapping and R2* measured changes during white matter lesion development in multiple sclerosis: myelin breakdown, myelin debris degradation and removal, and iron accumulation. AJNR Am J Neuroradiol 2016;37:1629–35 doi:10.3174/ajnr.A4825 pmid:27256856

    Abstract/FREE Full Text
46. 46.↵
    1. Chen W,
    2. Gauthier SA,
    3. Gupta A, et al

    . Quantitative susceptibility mapping of multiple sclerosis lesions at various ages. Radiology 2014;271:183–92 doi:10.1148/radiol.13130353 pmid:24475808

    CrossRefPubMed
47. 47.↵
    1. Harrison DM,
    2. Li X,
    3. Liu H, et al

    . Lesion heterogeneity on high-field susceptibility MRI is associated with multiple sclerosis severity. AJNR Am J Neuroradiol 2016;37:1447–53 doi:10.3174/ajnr.A4726 pmid:26939635

    Abstract/FREE Full Text
48. 48.↵
    1. Dziedzic T,
    2. Metz I,
    3. Dallenga T, et al

    . Wallerian degeneration: a major component of early axonal pathology in multiple sclerosis. Brain Pathol 2010;20:976–85 doi:10.1111/j.1750-3639.2010.00401.x pmid:20477831

    CrossRefPubMedWeb of Science
49. 49.↵
    1. Filippi M,
    2. Rocca MA,
    3. Barkhof F, et al

    ; Attendees of the Correlation between Pathological MRI Findings in MS Workshop. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol 2012;11:349–60 doi:10.1016/S1474-4422(12)70003-0 pmid:22441196

    CrossRefPubMedWeb of Science
50. 50.↵
    1. Lommers E,
    2. Simon J,
    3. Reuter G, et al

    . Multiparameter MRI quantification of microstructural tissue alterations in multiple sclerosis. Neuroimage Clin 2019;23:101879 doi:10.1016/j.nicl.2019.101879 pmid:31176293

    CrossRefPubMed
51. 51.↵
    1. West J,
    2. Aalto A,
    3. Tisell A, et al

    . Normal-appearing and diffusely abnormal white matter in patients with multiple sclerosis assessed with quantitative MR. PLoS One 2014;9:e95161 doi:10.1371/journal.pone.0095161 pmid:24747946

    CrossRefPubMed
52. 52.↵
    1. Chen W,
    2. Zhang Y,
    3. Mu K, et al

    . Quantifying the susceptibility variation of normal-appearing white matter in multiple sclerosis by quantitative susceptibility mapping. AJR Am J Roentgenol 2017;209:889–94 doi:10.2214/AJR.16.16851 pmid:28705068

    CrossRefPubMed
53. 53.↵
    1. Cifelli A,
    2. Arridge M,
    3. Jezzard P, et al

    . Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 2002;52:650–53 doi:10.1002/ana.10326 pmid:12402265

    CrossRefPubMedWeb of Science
54. 54.↵
    1. Mahajan KR,
    2. Nakamura K,
    3. Cohen JA, et al

    . Intrinsic and extrinsic mechanisms of thalamic pathology in multiple sclerosis. Ann Neurol 2020;88:81–92 doi:10.1002/ana.25743 pmid:32286701

    CrossRefPubMed
55. 55.↵
    1. Vercellino M,
    2. Masera S,
    3. Lorenzatti M, et al

    . Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J Neuropathol Exp Neurol 2009;68:489–502 doi:10.1097/NEN.0b013e3181a19a5a pmid:19525897

    CrossRefPubMed
56. 56.↵
    1. Elkady AM,
    2. Cobzas D,
    3. Sun H, et al

    . Five year iron changes in relapsing-remitting multiple sclerosis deep gray matter compared to healthy controls. Mult Scler Relat Disord 2019;33:107–15 doi:10.1016/j.msard.2019.05.028 pmid:31181540

    CrossRefPubMed
57. 57.↵
    1. Hernández-Torres E,
    2. Wiggermann V,
    3. Machan L, et al

    . Increased mean R2* in the deep gray matter of multiple sclerosis patients: have we been measuring atrophy? J Magn Reson Imaging 2019;50:201–08 doi:10.1002/jmri.26561 pmid:30511803

    CrossRefPubMed
58. 58.↵
    1. Khalil M,
    2. Langkammer C,
    3. Pichler A, et al

    . Dynamics of brain iron levels in multiple sclerosis: a longitudinal 3T MRI study. Neurology 2015;84:2396–2402 doi:10.1212/WNL.0000000000001679 pmid:25979698

    CrossRefPubMed
59. 59.↵
    1. Pontillo G,
    2. Petracca M,
    3. Monti S, et al

    . Unraveling deep gray matter atrophy and iron and myelin changes in multiple sclerosis. AJNR Am J Neuroradiol 2021;42:1223–30 doi:10.3174/ajnr.A7093 pmid:33888456

    Abstract/FREE Full Text
60. 60.↵
    1. Schweser F,
    2. Hagemeier J,
    3. Dwyer MG, et al

    . Decreasing brain iron in multiple sclerosis: the difference between concentration and content in iron MRI. Hum Brain Mapp 2021;42:1463–74 doi:10.1002/hbm.25306 pmid:33378095

    CrossRefPubMed
61. 61.↵
    1. Zivadinov R,
    2. Tavazzi E,
    3. Bergsland N, et al

    . Brain iron at quantitative MRI is associated with disability in multiple sclerosis. Radiology 2018;289:487–96 doi:10.1148/radiol.2018180136 pmid:30015589

    CrossRefPubMed
62. 62.↵
    1. Cobzas D,
    2. Sun H,
    3. Walsh AJ, et al

    . Subcortical gray matter segmentation and voxel-based analysis using transverse relaxation and quantitative susceptibility mapping with application to multiple sclerosis. J Magn Reson Imaging 2015;42:1601–10 doi:10.1002/jmri.24951 pmid:27418017

    CrossRefPubMed
63. 63.↵
    1. Lebel RM,
    2. Eissa A,
    3. Seres P, et al

    . Quantitative high-field imaging of sub-cortical gray matter in multiple sclerosis. Mult Scler 2012;18:433–41 doi:10.1177/1352458511428464 pmid:22032862

    CrossRefPubMed
64. 64.↵
    1. Rudko DA,
    2. Solovey I,
    3. Gati JS, et al

    . Multiple sclerosis: improved identification of disease-relevant changes in gray and white matter by using susceptibility-based MR imaging. Radiology 2014;272:851–64 doi:10.1148/radiol.14132475 pmid:24828000

    CrossRefPubMed
65. 65.↵
    1. Walsh AJ,
    2. Blevins G,
    3. Lebel RM, et al

    . Longitudinal MR imaging of iron in multiple sclerosis: an imaging marker of disease. Radiology 2014;270:186–96 doi:10.1148/radiol.13130474 pmid:23925273

    CrossRefPubMed
66. 66.↵
    1. Fujiwara E,
    2. Kmech JA,
    3. Cobzas D, et al

    . Cognitive implications of deep gray matter iron in multiple sclerosis. AJNR Am J Neuroradiol 2017;38:942–48 doi:10.3174/ajnr.A5109 pmid:28232497

    Abstract/FREE Full Text
67. 67.↵
    1. Hallgren B,
    2. Sourander P

    . The effect of age on the non-haemin iron in the human brain. Neurochem 1958;3:41–51 doi:10.1111/j.1471-4159.1958.tb12607.x pmid:13611557

    CrossRefPubMedWeb of Science
68. 68.↵
    1. Eshaghi A,
    2. Marinescu RV,
    3. Young AL, et al

    . Progression of regional grey matter atrophy in multiple sclerosis. Brain 2018;141:1665–77 doi:10.1093/brain/awy088 pmid:29741648

    CrossRefPubMed
69. 69.↵
    1. Haider L,
    2. Simeonidou C,
    3. Steinberger G, et al

    . Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron. J Neurol Neurosurg Psychiatry 2014;85:1386–95 doi:10.1136/jnnp-2014-307712 pmid:24899728

    Abstract/FREE Full Text
70. 70.↵
    1. Elkady AM,
    2. Cobzas D,
    3. Sun H, et al

    . Progressive iron accumulation across multiple sclerosis phenotypes revealed by sparse classification of deep gray matter. J Magn Reson Imaging 2017;46:1464–73 doi:10.1002/jmri.25682 pmid:28301067

    CrossRefPubMed
71. 71.↵
    1. Ropele S,
    2. Kilsdonk ID,
    3. Wattjes MP, et al

    . Determinants of iron accumulation in deep grey matter of multiple sclerosis patients. Mult Scler 2014;20:1692–98 doi:10.1177/1352458514531085 pmid:24787429

    CrossRefPubMed
72. 72.↵
    1. Hagemeier J,
    2. Zivadinov R,
    3. Dwyer MG, et al

    . Changes of deep gray matter magnetic susceptibility over 2 years in multiple sclerosis and healthy control brain. Neuroimage Clin 2018;18:1007–16 doi:10.1016/j.nicl.2017.04.008 pmid:29868452

    CrossRefPubMed
73. 73.↵
    1. Haacke EM,
    2. Cheng NY,
    3. House MJ, et al

    . Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 2005;23:1–25 doi:10.1016/j.mri.2004.10.001 pmid:15733784

    CrossRefPubMedWeb of Science
74. 74.↵
    1. Jonkman LE,
    2. Fleysher L,
    3. Steenwijk MD, et al

    . Ultra-high field MTR and qR2* differentiates subpial cortical lesions from normal-appearing gray matter in multiple sclerosis. Mult Scler 2016;22:1306–14 doi:10.1177/1352458515620499 pmid:26672996

    CrossRefPubMed
75. 75.↵
    1. Yao B,
    2. Hametner S,
    3. van Gelderen P, et al

    . 7 Tesla magnetic resonance imaging to detect cortical pathology in multiple sclerosis. PLoS One 2014;9:e108863 doi:10.1371/journal.pone.0108863 pmid:25303286

    CrossRefPubMed
76. 76.↵
    1. Peterson JW,
    2. Bö L,
    3. Mörk S, et al

    . Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001;50:389–400 doi:10.1002/ana.1123 pmid:11558796

    CrossRefPubMedWeb of Science
77. 77.↵
    1. Fischer MT,
    2. Wimmer I,
    3. Höftberger R, et al

    . Disease-specific molecular events in cortical multiple sclerosis lesions. Brain 2013;136:1799–1815 doi:10.1093/brain/awt110 pmid:23687122

    CrossRefPubMedWeb of Science
78. 78.↵
    1. Castellaro M,
    2. Magliozzi R,
    3. Palombit A, et al

    . Heterogeneity of cortical lesion susceptibility mapping in multiple sclerosis. AJNR Am J Neuroradiol 2017;38:1087–95 doi:10.3174/ajnr.A5150 pmid:28408633

    Abstract/FREE Full Text
79. 79.↵
    1. Magliozzi R,
    2. Howell OW,
    3. Reeves C, et al

    . A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 2010;68:477–93 doi:10.1002/ana.22230 pmid:20976767

    CrossRefPubMedWeb of Science
80. 80.↵
    1. Fukunaga M,
    2. Li TQ,
    3. van Gelderen P, et al

    . Layer-specific variation of iron content in cerebral cortex as a source of MRI contrast. Proc Natl Acad Sci U S A 2010;107:3834–39 doi:10.1073/pnas.0911177107 pmid:20133720

    Abstract/FREE Full Text
81. 81.↵
    1. Bagnato F,
    2. Hametner S,
    3. Boyd E, et al

    . Untangling the R2* contrast in multiple sclerosis: a combined MRI-histology study at 7.0 Tesla. PLoS One 2018;13:e0193839 doi:10.1371/journal.pone.0193839 pmid:29561895

    CrossRefPubMed
82. 82.↵
    1. Magliozzi R,
    2. Reynolds R,
    3. Calabrese M

    . MRI of cortical lesions and its use in studying their role in MS pathogenesis and disease course. Brain Pathol 2018;28:735–42 doi:10.1111/bpa.12642 pmid:30020563

    CrossRefPubMed
83. 83.↵
    1. Lema Dopico A,
    2. Choi S,
    3. Hua J, et al

    . Multi-layer analysis of quantitative 7 T magnetic resonance imaging in the cortex of multiple sclerosis patients reveals pathology associated with disability. Mult Scler 2021;27:2040–51 doi:10.1177/1352458521994556 pmid:33596719

    CrossRefPubMed